Wealth Effects LLC Invests $273,000 in DexCom, Inc. (NASDAQ:DXCM)

Wealth Effects LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,000 shares of the medical device company's stock, valued at approximately $273,000.

Several other large investors also recently added to or reduced their stakes in DXCM. Alpine Bank Wealth Management bought a new stake in DexCom during the first quarter worth about $40,000. Golden State Wealth Management LLC lifted its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Bessemer Group Inc. lifted its stake in DexCom by 2.8% during the first quarter. Bessemer Group Inc. now owns 949,091 shares of the medical device company's stock worth $64,812,000 after purchasing an additional 25,459 shares during the last quarter. Lecap Asset Management Ltd. lifted its stake in DexCom by 124.4% during the first quarter. Lecap Asset Management Ltd. now owns 56,872 shares of the medical device company's stock worth $3,884,000 after purchasing an additional 31,525 shares during the last quarter. Finally, Win Advisors Inc. bought a new stake in DexCom during the first quarter worth about $799,000. Institutional investors own 97.75% of the company's stock.

DexCom Trading Up 1.5%

NASDAQ:DXCM traded up $1.29 during mid-day trading on Friday, reaching $86.33. 4,632,374 shares of the company's stock traded hands, compared to its average volume of 4,393,450. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The firm has a market capitalization of $33.85 billion, a price-to-earnings ratio of 64.43, a PEG ratio of 1.81 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The company has a 50 day moving average price of $81.34 and a 200-day moving average price of $79.54.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company posted $0.32 EPS. The firm's revenue was up 12.5% on a year-over-year basis. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the sale, the executive vice president now directly owns 95,602 shares in the company, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,724 shares of company stock worth $2,157,034. Company insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on DXCM. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Piper Sandler dropped their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Canaccord Genuity Group lifted their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Barclays lifted their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.